Board

Chairman of the BoD
Peter Høngaard Andersen, cand.scient., dr.med.

EVP Research at Lundbeck A/S (since 2003; other positions at Lundbeck A/S 1999-2003)
VP Research in Arcadia Pharmaceutical (1997-1998)
various positions in Novo-Nordisk (1984-1997)
Chairman of BRIC

BoD
Claus Juan Møller-San Pedro, M.D., Ph.D.

BoD
Kristian Helin, Ph.D.

World leader in the field of oncology, epigenetics and histone modifying enzymes
Founded EpiTherapeutics with members of his laboratory at Biotech Research & Innovation Centre (BRIC), University of Copenhagen
Professor and Founding Director of BRIC, University of Copenhagen and Danish national Research Foundation’s Centre for Epigenetics
More than 100 papers in high impact journals including Nature, Cell and Genes & Development
Former divisional director of the European Institute of Oncology in Milan

BoD
Carsten Schou, Ph.D.

Partner of SEED Capital Management I/S
Director of Symbion Capital I A/S
Member of the Board of Celltrix AB, Evolva A/S, Zgene A/S, NeuroKey A/S, Valderm Aps and BRIC
Previously Director of Research at ALK-Abelló A/S and partner in Danske Private Equity Life Science

BoD
Stephan Christgau, Ph.D.

Investment Director of Novo Seeds, the early stage investment program of Novo A/S
Executive Vice President and Chief Operating Officer at Osteologix Inc. (until 2007)
Worked in the metabolic bone disease and arthritis areas in Nordic Bioscience and Osteometer Biotech and as a protein chemist in Novo Nordisk and at University of California, San Francisco
Author of more than 60 scientific publications and inventor on more than 30 patent families

BoD
Mette Kirstine Agger, M. Sc., MBA

Executive Director, Head of LFI Life Science Investments
Co-founder and CEO, 7TM Pharma (2000-2009)
Director of Business Development and Licensing, Member of the management group, NeuroSearch (1995-2000)
Co-founder of several biotech companies, several board of director positions